Literature DB >> 25374897

Mini-review: androgen receptor phosphorylation in prostate cancer.

Garrett Daniels1, Zhiheng Pei2, Susan K Logan3, Peng Lee4.   

Abstract

Androgen receptor (AR) plays an important role in the tumorigenesis and progression of prostate cancer (PCa), and is the primary therapeutic target for PCa treatment. AR activity can be regulated via phosphorylation at multiple phosphorylation sites within the protein. Modifications by phosphorylation alter AR function, including its cellular localization, stability and transcriptional activity, ultimately leading to changes in cancer cell biology and disease progression. Here we present a brief overview of AR phosphorylation sites in PCa, focusing on functional roles of phospho-AR (p-AR) species, relevance in PCa disease progression, and potential as biomarkers and/or therapeutic targets through the use of kinase inhibitors. Additionally, recent evidence has shown the important role of AR activity in the cancer associated stroma on PCa growth and progression. The phosphorylation status of epithelial and stromal AR may be distinct; however, the current data available on stromal AR phosphorylation is limited. Further research will determine global view on the synergistic effects of phosphorylation across multiple AR sites in both epithelial and stromal cells and validate whether together they can be used as prognostic markers and/or effective therapeutic targets for PCa.

Entities:  

Keywords:  Androgen receptor; phosphorylation; prostate cancer

Year:  2013        PMID: 25374897      PMCID: PMC4219286     

Source DB:  PubMed          Journal:  Am J Clin Exp Urol        ISSN: 2330-1910


  38 in total

Review 1.  A review of African American-white differences in risk factors for cancer: prostate cancer.

Authors:  Irina Mordukhovich; Paul L Reiter; Danielle M Backes; Leila Family; Lauren E McCullough; Katie M O'Brien; Hilda Razzaghi; Andrew F Olshan
Journal:  Cancer Causes Control       Date:  2010-12-24       Impact factor: 2.506

2.  Phosphorylation of the androgen receptor by a nuclear cAMP-independent protein kinase.

Authors:  S A Goueli; J L Holtzman; K Ahmed
Journal:  Biochem Biophys Res Commun       Date:  1984-09-17       Impact factor: 3.575

3.  Regulation of a novel androgen receptor target gene, the cyclin B1 gene, through androgen-dependent E2F family member switching.

Authors:  Yirong Li; David Y Zhang; Qinghu Ren; Fei Ye; Xin Zhao; Garrett Daniels; Xinyu Wu; Brian Dynlacht; Peng Lee
Journal:  Mol Cell Biol       Date:  2012-04-16       Impact factor: 4.272

4.  Post-translational modification of the androgen receptor.

Authors:  Daniel Gioeli; Bryce M Paschal
Journal:  Mol Cell Endocrinol       Date:  2011-07-24       Impact factor: 4.102

5.  Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells.

Authors:  Xi Yang; Zhiyong Guo; Feng Sun; Wei Li; Alan Alfano; Hermela Shimelis; Mingyuan Chen; Angela M H Brodie; Hegang Chen; Zhen Xiao; Timothy D Veenstra; Yun Qiu
Journal:  J Biol Chem       Date:  2011-08-30       Impact factor: 5.157

6.  Prostatic intraepithelial neoplasia and adenocarcinoma in mice expressing a probasin-Neu oncogenic transgene.

Authors:  Zhe Li; Matthias Szabolcs; Joseph D Terwilliger; Argiris Efstratiadis
Journal:  Carcinogenesis       Date:  2006-01-09       Impact factor: 4.944

Review 7.  The androgen/androgen receptor axis in prostate cancer.

Authors:  Eric G Bluemn; Peter S Nelson
Journal:  Curr Opin Oncol       Date:  2012-05       Impact factor: 3.645

8.  Site-specific androgen receptor serine phosphorylation linked to epidermal growth factor-dependent growth of castration-recurrent prostate cancer.

Authors:  Liliana A Ponguta; Christopher W Gregory; Frank S French; Elizabeth M Wilson
Journal:  J Biol Chem       Date:  2008-05-29       Impact factor: 5.157

9.  PSA screening and deaths from prostate cancer after diagnosis--a population based analysis.

Authors:  Mitchell S Wachtel; Thomas Nelius; Allan L Haynes; Scott Dahlbeck; Werner de Riese
Journal:  Prostate       Date:  2013-05-06       Impact factor: 4.104

10.  Androgen receptor phosphorylation at serine 515 by Cdk1 predicts biochemical relapse in prostate cancer patients.

Authors:  J M Willder; S J Heng; P McCall; C E Adams; C Tannahill; G Fyffe; M Seywright; P G Horgan; H Y Leung; M A Underwood; J Edwards
Journal:  Br J Cancer       Date:  2012-12-04       Impact factor: 7.640

View more
  5 in total

1.  Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer.

Authors:  Michael A Gordon; Nicholas C D'Amato; Haihua Gu; Beatrice Babbs; Julia Wulfkuhle; Emanuel F Petricoin; Isela Gallagher; Ting Dong; Kathleen Torkko; Bolin Liu; Anthony Elias; Jennifer K Richer
Journal:  Mol Cancer Ther       Date:  2017-05-03       Impact factor: 6.261

Review 2.  Membrane-Initiated Estrogen, Androgen, and Progesterone Receptor Signaling in Health and Disease.

Authors:  Franck Mauvais-Jarvis; Carol A Lange; Ellis R Levin
Journal:  Endocr Rev       Date:  2022-07-13       Impact factor: 25.261

3.  Inhibitor of p52 NF-κB subunit and androgen receptor (AR) interaction reduces growth of human prostate cancer cells by abrogating nuclear translocation of p52 and phosphorylated AR(ser81).

Authors:  Farideh Mehraein-Ghomi; Dawn R Church; Cynthia L Schreiber; Ashley M Weichmann; Hirak S Basu; George Wilding
Journal:  Genes Cancer       Date:  2015-09

4.  Triptolide Inhibits the AR Signaling Pathway to Suppress the Proliferation of Enzalutamide Resistant Prostate Cancer Cells.

Authors:  Yangyang Han; Weiwei Huang; Jiakuan Liu; Dandan Liu; Yangyan Cui; Ruimin Huang; Jun Yan; Ming Lei
Journal:  Theranostics       Date:  2017-04-20       Impact factor: 11.556

Review 5.  Future Aspects of CDK5 in Prostate Cancer: From Pathogenesis to Therapeutic Implications.

Authors:  Muhammet Oner; Eugene Lin; Mei-Chih Chen; Fu-Ning Hsu; G M Shazzad Hossain Prince; Kun-Yuan Chiu; Chieh-Lin Jerry Teng; Tsung-Ying Yang; Hsin-Yi Wang; Chia-Herng Yue; Ching-Han Yu; Chih-Ho Lai; Jer-Tsong Hsieh; Ho Lin
Journal:  Int J Mol Sci       Date:  2019-08-09       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.